-
Mashup Score: 0
The secondary analysis of the phase 3 CONDOR study showed that given prior positron emission tomography, piflufolastat F 18 demonstrated changes in intended management, reinforcing the agent’s clinical utility.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
ASCO GU 2023 CONDOR study, phase 3 CONDOR trial of patients with biochemically recurrent prostate cancer, clinical utility of piflufolastat F18 scanning, piflufolastat F18-PET/CT.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent #ProstateCancer and low PSA levels: a secondary analysis of results from the #CONDOR study. @pouliotfredUL @chudequebec. @ASCO #GU23 > https://t.co/DJSlanmEHS @zklaassen_md https://t.co/2xhnGfSN4a
-
-
Mashup Score: 5
CONDOR study prostate cancer, CONDOR study, CONDOR DCFPyLPET/ CT, DCFPyLPET/ CT, subanalysis of correct localization rate and positive predictive value of PSMA-targeted 18F-DCFPyLPET/ CT for each of the pre-defined standard of truth criteria for the CONDOR prospective phase 3 study
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
PSMA-targeted #Imaging with 18F-DCFPyL-PET/CT in pts with biochemically recurrent #ProstateCancer #CONDOR - subanalysis of correct localization rate and positive predictive value by Standard of Truth. @pouliotfredUL @chudequebec > https://t.co/d6gUbS4iKq #ASCO21 @zklaassen_md https://t.co/Xv6WSfQ1O5
-
-
Mashup Score: 018F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen - 2 year(s) ago
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the Clinical Cancer Research publication on the results from the CONDOR Phase 3, multicenter study. In particular, conventional imaging performs poorly when PSA levels are low, less than 2 ng/mL, and the use of novel PET radiotracers may address this issue and provide more sensitive imaging. CONDOR was a prospective…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3
localize biochemically recurrent prostate cancer after local therapy SNMMI 2021. 18F-DCFPyL-PET/CT by anatomic region: prostate/prostate bed, pelvic lymph nodes, and extra-pelvic regions (including lymph nodes, bone, and viscera/soft tissue) SNMMI 2021.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
A phase 3 study of 18F-DCFPyL-PET/CT in patients with biochemically recurrent #ProstateCancer #CONDOR: An analysis of disease detection rate and positive predictive value by anatomic region. Steven Rowe @HopkinsMedicine > https://t.co/7zytUS5hyl #SNMMI21 @zklaassen_md @SNM_MI https://t.co/okUMyTSjOk
-
-
Mashup Score: 5
SUO 2021 Prostate-specific membrane antigen (PSMA)-targeted imaging, 68-Gallium and Piflufolastat F-18, CONDOR trial, Piflufolastat F-18, Piflufolastat F 18-PET/CT scans, PSA response following radiation therapy.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Diagnostic performance of piflufolastat F 18-PET/CT in men with biochemical recurrence of #ProstateCancer after definitive treatment: A #CONDOR study subanalysis. Presented by @pcarroll_ @UCSFUrology. #SUO21 written coverage by @WallisCJD @UofT > https://t.co/TJwVbdumBC @UroOnc https://t.co/Pi5QiqNzJM
-
-
Mashup Score: 0OSPREY and CONDOR Trials - Evaluating F-18 DCFPyL PSMA Imaging for Prostate Cancer - Michael J. Morris - 2 year(s) ago
A Step Towards Personalized Medicine: PSMA-PET Imaging in Prostate Cancer F-18 DCFPyL PSMA Imaging for Prostate Cancer: OSPREY and CONDOR. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3Practical Application of 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: The CONDOR Study - Michael Morris - 2 year(s) ago
The CONDOR trial was one of two studies that supported the United States Federal Drug Administration (FDA) submission and subsequent approval of DCFPyL, an 18F radiolabeled PSMA directed PET tracer. The CONDOR trial focused specifically on the rising, the biochemically relapsed patient population, those who had surgery or radiation as their definitive primary therapy, biochemically relapsed,…
Source: UroTodayCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 3OSPREY and CONDOR Trials - Evaluating F-18 DCFPyL PSMA Imaging for Prostate Cancer - Michael J. Morris - 2 year(s) ago
A Step Towards Personalized Medicine: PSMA-PET Imaging in Prostate Cancer F-18 DCFPyL PSMA Imaging for Prostate Cancer: OSPREY and CONDOR. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Practical Application of 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: The CONDOR Study - Michael Morris - 2 year(s) ago
The CONDOR trial was one of two studies that supported the United States Federal Drug Administration (FDA) submission and subsequent approval of DCFPyL, an 18F radiolabeled PSMA directed PET tracer. The CONDOR trial focused specifically on the rising, the biochemically relapsed patient population, those who had surgery or radiation as their definitive primary therapy, biochemically relapsed,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
In the phase 3 #CONDOR study, investigators found piflufolastat F 18 prior to PET scanning to show changes in intended management in 39.1% of patients with a PSA level below 0.5 ng/mL. #pcsm #GU23 https://t.co/T4NxnK54J2